ADMA Biologics Inc
As of Oct 22, 2026, ADMA Biologics is in Stage 1, the basing phase, now in week 11 (since Aug 11, 2026). It closed at $10.95, 46.3% below its 52-week high and below its 200-day average, which is falling.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ADMA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ADMA among Biotechnology264th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …264 | ADMA | Stage 1 · wk 11 | 36 | +12.9% |
ADMA Biologics: quick answers
What stage is ADMA Biologics in?
As of Oct 22, 2026, ADMA Biologics (ADMA) is in Stage 1, the basing phase. It entered Stage 1 on Aug 11, 2026 and is in week 11. What the four stages mean
Is ADMA Biologics in an uptrend?
Not yet. ADMA Biologics is in Stage 1, a base that can come before an uptrend. It trades 1.9% below its 200-day average, which is falling.
How far is ADMA Biologics from its 52-week high?
ADMA Biologics closed at $10.95 on Oct 22, 2026, 46.3% below its 52-week high of $20.38. Its 52-week low is $7.60.
How has ADMA Biologics performed over the past year?
As of Oct 22, 2026, ADMA Biologics is down 25.6% over the past year and down 38.8% so far in 2026.
Which sector and industry is ADMA Biologics in?
ADMA Biologics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.